Baxter Posts Wider 4Q Loss, Says Results Missed Expectations

Dow Jones
02/12

By Nicholas G. Miller

 

Baxter International reported a wider fourth-quarter loss and said that despite sales growth across categories, the quarter's results missed its expectations.

Shares fell 15% to $19.02 in premarket trading.

The healthcare company reported a wider loss of $1.13 billion, or $2.19 a share, compared with a loss of $512 million, or $1 a share, the year prior. The loss included a goodwill impairment charge of $485 million related to the Front Line Care reporting unit.

Adjusted earnings were 36 cents a share. The company said adjusted profit was hurt by unfavorable product mix, non-recurring items including inventory adjustments and a higher effective tax rate.

Sales from continuing operations rose 8% to $2.97 billion. Medical products and therapies revenue rose 6%, healthcare systems and technologies sales increased 5%, while pharmaceutical sales rose 4%.

"While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations," said Chief Executive Andrew Hider.

The company guided for 2026 sales from continuing operations to be flat to up 1% and adjusted earnings from continuing operations of $1.85 to $2.05 a share.

 

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

 

(END) Dow Jones Newswires

February 12, 2026 07:50 ET (12:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10